# TriNetX

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/trinetx

- Industry: Healthcare IT
- Headquarters: Cambridge, US
- Website: www.trinetx.com
- Total disclosed funding: $42M
- Latest round: Series D (Mar 13, 2019)
- Investors on record: 6

## About

TriNetX LLC, based in the US, operates a federated network providing real-world data solutions for life sciences and healthcare sectors, enhancing clinical trial efficiency and supporting patient outcome improvements.TriNetX LLC specializes in real-world data analytics for the healthcare sector, enabling research and operational improvements. Founded in 2013, the company is headquartered in Cambridge, US. Its CEO, Gadi Lachman, leads the firm, which has successfully completed 5 investment deals, with the most recent deal occurring on September 21, 2020, when Carlyle Group acquired a majority stake for an undisclosed amount. TriNetX has raised a total of USD 10.00 mn through its funding rounds, including the latest round of USD 10.00 mn.TriNetX, LLC operates a federated network focused on real-world data for the life sciences and healthcare sectors. The company provides advanced analytics and intelligence solutions designed to enhance clinical trial protocol design, streamline trial operations, and support pharmacovigilance efforts. Their core offerings are centered around their self-service platform, which delivers de-identified electronic health record datasets and analytics tools to facilitate research and improve patient outcomes. TriNetX serves a diverse client base that includes pharmaceutical companies, healthcare providers, and academic institutions globally, with specific markets in North America, Europe, and the Asia-Pacific region. The platform enables users to conduct real-time querying of patient records, assess treatment patterns, and generate insights that aid in drug development and post-market surveillance.TriNetX generates revenue primarily through subscription-based access to its platform and services, targeting life sciences organizations and healthcare providers seeking to leverage real-world evidence for research and clinical applications. Clients enter into partnership agreements that grant them access to TriNetX's extensive datasets and analytics capabilities to enhance the efficiency of their clinical trials and improve patient care. Pricing structures are tailored based on the specific needs of each client, including features such as advanced analytics and consulting services. The company's flagship offerings, such as TriNetX LIVE™ and EVIDEX®, form the backbone of its revenue-generating activities, supporting a wide range of applications from clinical trial optimization to drug safety analysis.Looking ahead, TriNetX aims to enhance its offerings by developing new products tailored for specific research needs in the life sciences sector. With the recent funding deal completed in September 2020, the company plans to allocate resources towards expanding its platform capabilities and increasing its footprint in emerging markets, particularly focusing on regions in Asia-Pacific by 2023. This expansion strategy aligns with their goal to provide comprehensive data solutions that cater to the evolving demands of healthcare providers and researchers.

## Funding rounds

- Series D, Mar 13, 2019, $40M — MPM BioImpact, Merck Global Health Innovation Fund, ITOCHU Technology Ventures, F2 Ventures, Deerfield Management, Mitsui & Co.
- Series A, Sep 23, 2013, $1.6M — MPM BioImpact

## Investors

- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series A, Series D
- Merck Global Health Innovation Fund (https://capitalatlas.ai/funds/merck-global-health-innovation-fund) — Series D
- ITOCHU Technology Ventures (https://capitalatlas.ai/funds/itochu-technology-ventures) — Series D
- F2 Ventures (https://capitalatlas.ai/funds/f2-ventures) — Series D
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series D
- Mitsui & Co. — Series D